Literature DB >> 31807417

Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").

Mayer Fishman1,2,3.   

Abstract

Entities:  

Year:  2019        PMID: 31807417      PMCID: PMC6842782          DOI: 10.21037/tau.2019.09.19

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
  15 in total

1.  Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.

Authors:  A Yagoda; R C Watson; J C Gonzalez-Vitale; H Grabstald; W F Whitmore
Journal:  Cancer Treat Rep       Date:  1976-07

2.  Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.

Authors:  Jean-Michel Lavoie; Peter C Black; Bernhard J Eigl
Journal:  J Urol       Date:  2019-06-07       Impact factor: 7.450

3.  Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authors:  Joaquim Bellmunt; Ronald de Wit; David J Vaughn; Yves Fradet; Jae-Lyun Lee; Lawrence Fong; Nicholas J Vogelzang; Miguel A Climent; Daniel P Petrylak; Toni K Choueiri; Andrea Necchi; Winald Gerritsen; Howard Gurney; David I Quinn; Stéphane Culine; Cora N Sternberg; Yabing Mai; Christian H Poehlein; Rodolfo F Perini; Dean F Bajorin
Journal:  N Engl J Med       Date:  2017-02-17       Impact factor: 91.245

4.  Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Linda T Vahdat; Sara M Tolaney; Steven J Isakoff; Jennifer R Diamond; Joyce O'Shaughnessy; Rebecca L Moroose; Alessandro D Santin; Vandana G Abramson; Nikita C Shah; Hope S Rugo; David M Goldenberg; Ala M Sweidan; Robert Iannone; Sarah Washkowitz; Robert M Sharkey; William A Wegener; Kevin Kalinsky
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 91.245

5.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal:  Lancet       Date:  2017-12-18       Impact factor: 79.321

6.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

7.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

8.  Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.

Authors:  Earle F Burgess; Chad Livasy; Aaron Hartman; Myra M Robinson; James Symanowski; Caroline Naso; Shannon Doherty; Renato Guerrieri; Stephen Riggs; Claud M Grigg; Peter E Clark; Derek Raghavan
Journal:  Urol Oncol       Date:  2019-01-17       Impact factor: 3.498

Review 9.  Antibody-Drug Conjugates in Bladder Cancer.

Authors:  Panagiotis J Vlachostergios; Christopher D Jakubowski; Muhammad J Niaz; Aileen Lee; Charlene Thomas; Amy L Hackett; Priyanka Patel; Naureen Rashid; Scott T Tagawa
Journal:  Bladder Cancer       Date:  2018-07-30

10.  Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Authors:  Y Fradet; J Bellmunt; D J Vaughn; J L Lee; L Fong; N J Vogelzang; M A Climent; D P Petrylak; T K Choueiri; A Necchi; W Gerritsen; H Gurney; D I Quinn; S Culine; C N Sternberg; K Nam; T L Frenkl; R F Perini; R de Wit; D F Bajorin
Journal:  Ann Oncol       Date:  2019-06-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.